hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-11. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
A diplomatic crisis began in 2025 when the Donald Trump's second presidency of the United States administration sought to annex Greenland, an autonomous territory of the Danish Realm—a treaty ally of the United States and co-member of NATO, and a member of the European Union (EU). The crisis intensified in early 2026 when Trump refused to rule out the use of military force for this annexation and threatened a 25% import tax on goods from several European nations unless Denmark ceded the territory to the United States. Denmark's refusal was supported by the EU and several other NATO members, reigniting earlier concerns of a US–EU trade war. Within weeks, Trump backed down, pledging not to use force or tariffs to annex Greenland. Trump had tried to purchase Greenland during his first presidency. After his 2024 re-election, in January 2026, he said "it may be a choice" whether to preserve NATO or seize Greenland, and in Dear Jonas, a letter leaked by Norwegian Prime Minister Jonas Gahr Støre, Trump had said that he "no longer [felt] an obligation to think purely of Peace" after not receiving the Nobel Peace Prize. A report by the Danish Defence Intelligence Service mentioned the United States as a potential threat to national security for the first time in its history, and Danish officials raised concerns about reports that Director of National Intelligence Tulsi Gabbard had assigned agents to spy on Greenland. The Greenlandic and Danish prime ministers rejected any American takeover, saying they would defend Greenland in the event of an attack.
== Development == The peritoneum develops ultimately from the mesoderm of the trilaminar embryo. As the mesoderm differentiates, one region known as the lateral plate mesoderm splits to form two layers separated by an intraembryonic coelom. These two layers develop later into the visceral and parietal layers found in all serous cavities, including the peritoneum. As an embryo develops, the various abdominal organs grow into the abdominal cavity from structures in the abdominal wall. In this process they become enveloped in a layer of peritoneum. The growing organs "take their blood vessels with them" from the abdominal wall, and these blood vessels become covered by peritoneum, forming a mesentery. Peritoneal folds develop from the ventral and dorsal mesentery of the embryo.
== Inhibition of the glyoxylate cycle == Due to the central role of the glyoxylate cycle in the metabolism of pathogenic species including fungi and bacteria, enzymes of the glyoxylate cycle are current inhibition targets for the treatment of diseases. Most reported inhibitors of the glyoxylate cycle target the first enzyme of the cycle (ICL). Inhibitors were reported for Candida albicans for potential use as antifungal agents. The mycobacterial glyoxylate cycle is also being targeted for potential treatments of tuberculosis.
A TTP insurgent was killed in a military operation in North Waziristan while a woman was injured in a grenade attack in South Waziristan. Mullah Khel tribesmen repelled militants infiltrating into the village of Maulana Zeenatullah Badan in Orakzai District. A quadcopter attack in South Waziristan killed three civilians and wounded four, two more were injured in a separate quadcopter attack there while three were injured in a quadcopter attack in Bannu District. Pakistan initiated "Operation Shaban" in Balochistan. On 6 July, clashes between Pakistani and Afghan forces continued in Khyber District while nine dead bodies of tribesmen were recovered from Quetta District following a strike by 30-40 TTP insurgents on a meeting of what they claimed to be military collaborators. On 7 July, TTP militants attacked a police post in Ziarat District killing nine Policemen including two SHOs whereas 15 militants were killed in retaliatory clearance operations, several policemen were also captured by the TTP of which eighteen were later executed. CPEC brigde in Bannu District was destroyed by insurgents. An ATF personnel was killed in a skirmish with TTP in Quetta. A quadcopter strike in Bannu District killed one civilian and wounded four others. TTP captured a Pakistani joint post in Harnai District seizing weapons, equipment and vehicles.
Sources: en.wikipedia.org
Difelikefalin, sold under the brand name Korsuva, is an opioid peptide used for the treatment of moderate to severe itch. It acts as a peripherally-restricted, highly selective agonist of the κ-opioid receptor (KOR). Difelikefalin acts as an analgesic by activating KORs on peripheral nerve terminals and KORs expressed by certain immune system cells. Activation of KORs on peripheral nerve terminals results in the inhibition of ion channels responsible for afferent nerve activity, causing reduced transmission of pain signals, while activation of KORs expressed by immune system cells results in reduced release of proinflammatory, nerve-sensitizing mediators (e.g., prostaglandins). Difelikefalin was approved for medical use in the United States in August 2021. The U.S. Food and Drug Administration considers it to be a first-in-class medication.
Oxytocin (medication), a medication made from oxytocin used to start or strengthen contraction of the uterus during childbirth "Oxytocin", a song by Billie Eilish from her 2021 album Happier Than Ever.
==== Increased blood pressure ==== In a study done by ML Maitland, a mean blood pressure increase of 8.2 mm Hg systolic and 6.5 mm Hg diastolic was reported in the first 24 hours after the first treatment with sorafenib, a VEGF pathway inhibitor.
Sources: en.wikipedia.org
On 8 March, Pakistani officials stated that since the start of hostilities, 583 Afghan Taliban operatives had been killed and more than 795 injured. They added that Pakistani forces had destroyed 242 check-posts, captured 38 others, destroyed 213 tanks, armored vehicles, and artillery guns, and targeted 64 locations across Afghanistan in air strikes. Pakistani officials also said that they foiled an infiltration attempt along the Pakistan–Afghanistan border near the Chaman sector, killing one Taliban soldier while others fled the area. Elsewhere, Pakistani security forces carried out intelligence-based operation in five districts of the country, killing 13 Pakistani Taliban militants. In Pakistan's North Waziristan, two civilians were killed and three others were injured when a mortar shell fired by Taliban forces landed in a village. A child was killed and his 11 family members were wounded in a quadcopter strike in South Waziristan. Meanwhile, Taliban officials said that they shot a reconnaissance drone belonging to Pakistani forces in Nangarhar province. Two militants were killed in a Pakistani precision airstrike in Bannu District. In Kunar province, residents stated that the Taliban had forced them to participate in a protest march against Pakistan in Asadabad on 7 March. According to them, Taliban authorities instructed each tribal elder to bring at least five people to the protest.
Irvine stated that he "criticized Freud and other theorists for projecting male constructs of sexuality onto women" and "viewed the clitoris as the main center of sexual response". He considered the vagina to be "relatively unimportant" for sexual satisfaction, relaying that "few women inserted fingers or objects into their vaginas when they masturbated". Believing that vaginal orgasms are "a physiological impossibility" because the vagina has insufficient nerve endings for sexual pleasure or climax, he "concluded that satisfaction from penile penetration [is] mainly psychological or perhaps the result of referred sensation". Masters and Johnson's research, as well as Shere Hite's, generally supported Kinsey's findings about the female orgasm. Masters and Johnson were the first researchers to determine that the clitoral structures surround and extend along and within the labia. They observed that both clitoral and vaginal orgasms have the same stages of physical response, and found that the majority of their subjects could only achieve clitoral orgasms, while a minority achieved vaginal orgasms. On that basis, they argued that clitoral stimulation is the source of both kinds of orgasms, reasoning that the clitoris is stimulated during penetration by friction against its hood. The research came at the time of the second-wave feminist movement, which inspired feminists to reject the distinction made between clitoral and vaginal orgasms.
The second step in lipid metabolism is absorption of fats. Short chain fatty acids can be absorbed in the stomach, while most absorption of fats occurs only in the small intestines. Once the triglycerides are broken down into individual fatty acids and glycerols, along with cholesterol, they will aggregate into structures called micelles. Fatty acids and monoglycerides leave the micelles and diffuse across the membrane to enter the intestinal epithelial cells. In the cytosol of epithelial cells, fatty acids and monoglycerides are recombined back into triglycerides. In the cytosol of epithelial cells, triglycerides and cholesterol are packaged into bigger particles called chylomicrons which are amphipathic structures that transport digested lipids. Chylomicrons will travel through the bloodstream to enter adipose and other tissues in the body.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.